M.D. Anderson group unveils new p53 marker

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

William R. Kennedy, MD

April 28th 2025

FDA Approves Multi-Dose Thiotepa Vial for Breast and Ovarian Cancers

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

The FDA originally approved this thiotepa formulation as a therapy for patients with breast or ovarian cancers in June 2024.

Russ Conroy

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

The CHMP Recommends Acalabrutinib Combos For Approval in Untreated CLL

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Tim Cortese

Cretostimogene Grenadenorepvec Displays Efficacy in BCG-Unresponsive NMIBC

Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.

Complete response rates were observed consistently across patient subgroups in those with high-risk BCG-unresponsive non-muscle invasive bladder cancer.

Ashley Chan

April 29th 2025

Linvoseltamab Receives EU Approval for Relapsed/Refractory Multiple Myeloma

Complete response rates were observed consistently across patient subgroups in those with high-risk BCG-unresponsive non-muscle invasive bladder cancer.

Related Content

$The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.$

Roman Fabbricatore

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.

William R. Kennedy, MD

April 28th 2025

FDA Approves Multi-Dose Thiotepa Vial for Breast and Ovarian Cancers

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Russ Conroy

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

The CHMP Recommends Acalabrutinib Combos For Approval in Untreated CLL

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Tim Cortese

Cretostimogene Grenadenorepvec Displays Efficacy in BCG-Unresponsive NMIBC

Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.

Ashley Chan

April 29th 2025